U.S. FDA Approves AOP Health’s Rapiblyk™ (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting BWI U.S. FDA Approves AOP Health’s Rapiblyk™ (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting creativebharatgroup@gmail.com November 27, 2024 Vienna, Austria: AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria,... Read More Read more about U.S. FDA Approves AOP Health’s Rapiblyk™ (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting
